Gastric Cancer Therapeutics Market Growing With Highest Demand by 2026 – with Pfizer, Eli Lilly, GlaxoSmithKline plc, Kuhnil Pharmaceutical/Daiichi Sankyo, etc

Global Gastric Cancer Therapeutics Market – Insights

Gastric cancer develops within the inside layer of the stomach and is characterized by upper abdominal pain, heartburn, sudden weight loss, yellowing of the skin, blood in the stool, loss of appetite, and nausea. It can spread to other body parts such as lungs, liver, the lining of the abdomen, lymph nodes, and bones. Majority of gastric cancers are gastric carcinomas. Helicobacter pylori – a type of bacteria— is a major cause of gastric cancer, accounting for around 60% of the cases. The severity of the disease varies with the type of H. pylori. Other factors such as smoking and eating pickled vegetables are also responsible for gastric cancer. Around 1 in 10 cases of the disease are inherited and 1% to 3% of the cases are due to hereditary syndromes such as hereditary gastric cancer.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/194

According to World Cancer Research Fund International, 952,000 new cases of gastric cancer were diagnosed in 2012 and the disease was the fifth-most common type of cancer in the world. Therefore, various institutes, universities, and government bodies are focused on R&D of effective therapies for gastric cancer.

Gastric Cancer Therapeutics Market Taxonomy

On the basis of type of treatment, the global gastric cancer therapeutics market is segmented into:

• • Surgery
  • Targeted drugs therapy
  • Chemotherapy
  • Radiation therapy
  • Others

On the basis of end-user, the global gastric cancer therapeutics market is segmented into:

• • Hospitals
  • Clinics
  • Specialized cancer treatment centers
  • Ambulatory surgical centers
  • Others

On the basis of region, the global gastric cancer therapeutics market is segmented into:

• • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/194

Global Gastric Cancer Therapeutics Market: Drivers

High incidence of gastric cancer in Asia Pacific to boost growth of the overall global gastric cancer therapeutics market over the forecast period. The stage or phase of the disease during diagnosis determines the survival rate in gastric cancer. In Asia Pacific, majority of the geriatric population suffers from gastric cancer and most of the cases are detected at the later stage of the disease. Therefore, growing geriatric population in the region is also boosting growth of the market. Moreover, increasing health awareness may lead to early detection of the disease, thereby boosting growth of the global gastric cancer therapeutics market over the forecast period.

Currently, angiogenesis inhibitors, new chemotherapies, and HER2-targeted therapy are some of the treatment option for gastric cancer. However, demand for therapeutics for the treatment of HER2-negative stomach cancer is high and the demand for targeted therapies is increasing. Such scenario is expected to boost growth of the global gastric cancer therapeutics market.

Global Gastric Cancer Therapeutics Market: Regional Analysis 

North America is expected to hold dominant position in the global gastric cancer therapeutics market over the forecast period. This is attributed to high prevalence of gastric cancer in the U.S. For instance, according to National Cancer Institute, an estimated 79,843 people suffered from gastric cancer in the U.S. in 2013. According to the same source, gastric cancer represented 1.6% of the new cancer cases reported in the U.S. and 26,370 new cases of the disease were reported that led to 10,730 deaths in 2016.

Global Gastric Cancer Therapeutics Market: Competitive Landscape

Major players operating in the global gastric cancer therapeutics market include, Pfizer, Kuhnil Pharmaceutical/Daiichi Sankyo, Eli Lilly, GlaxoSmithKline plc., Ono Pharmaceutical/Bristol-Myers Squibb, BMS, Merck KGaA, Sanofi, Otsuka Holdings Co. Ltd., F. Hoffmann-La Roche Ltd., AstraZeneca, Jiangsu HengRui Medicine, Gilead Bioscience, Celgene/Taiho, Boston Biomedical, and Merck.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/gastric-cancer-therapeutics-market-194

Major players operating in the global gastric cancer therapeutics market are focused on launching new products to expand their product portfolio. For instance, in April 2019, F. Hoffmann-La Roche AG launched VENTANA HER2 Dual ISH DNA Probe Cocktail assay for the detection of the HER2 biomarker in breast and gastric cancer.

Major market players are focused on adopting collaboration strategies to develop novel therapies for gastric cancer. For instance, in February 2019, GlaxoSmithKline plc. and Merck KGaA entered into a global strategic alliance to jointly develop and commercialize M7824, an investigational bifunctional fusion protein immunotherapy under clinical development stage, for the treatment of human papillomavirus-associated cancers, biliary tract cancer (BTC), and gastric cancer.

Key market players are also focused on gaining regulatory approvals to expand their product portfolio. Fro instance, in August 2019, Taiho Pharmaceutical Co., Ltd. obtained additional indication of unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy for its anticancer agent LONSURF, an oral anticancer drug that uses the combination of trifluridine (antineoplastic nucleoside analogue) and tipiracil (a thymidine phosphorylase inhibitor), from the Japanese Ministry of Health, Labor and Welfare.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837